Kura Oncology created Caspian Therapeutics, which raised $50.0 million through a Series A preferred-stock financing, while Kura invested $4.3 million. Kura’s holdings represented approximately 49.2% of Caspian’s outstanding Capital Stock after the transaction, while Caspian assumed responsibility for developing and commercializing the transferred Assets in cardiometabolic diseases.

Key Highlights

  • Kura’s holdings represented approximately 49.2% of Caspian’s outstanding capital stock after the financing.
  • The assets transferred to Caspian include KO-7246 and related intellectual property, with reimbursement of up to $1.5 million available to Kura.
  • Kura and Caspian entered a services arrangement covering research, development and administrative support.

Kura Oncology, Inc. (NASDAQ: KURA) created Caspian Therapeutics to develop next-generation menin inhibitors for diabetes and other cardiometabolic diseases. Caspian raised $50.0 million through the sale of Series A preferred stock, while Kura invested $4.3 million in the financing.

Caspian Takes On Cardiometabolic Development

The financing closed on September 8, 2026. Afterward, Kura’s common-stock and preferred-stock interests represented approximately 49.2% of Caspian’s outstanding capital stock. Kura also transferred rights to next-generation menin inhibitors, including the internally designated compound KO-7246, along with related intellectual property and other assets. Caspian is responsible for development, regulatory and commercial activities involving products based on those assets in diabetes and other cardiometabolic diseases. Kura granted Caspian perpetual, worldwide, royalty-free rights under certain patents and data concerning ziftomenib for use in that field, while Caspian granted Kura corresponding rights under the transferred patents and know-how for research and development. The agreements also restrict each party from pursuing menin inhibitors outside its designated field for a defined period, subject to customary change-of-control exceptions. Kura agreed to provide research and development, general administrative and other mutually agreed services to Caspian for service fees. The services arrangement renews annually unless either party gives the required non-renewal notice, and it includes termination rights for convenience or uncured material breach.